Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¾Ç¼º ¼º»ó¼¼Æ÷Á¾ ¹× ±³¸ð¼¼Æ÷Á¾ÀÇ ÀûÁ¤ ¹æ»ç¼± Á¶»ç ¿µ¿ª¿¡ ´ëÇÑ °íÂû Optimal Radiation Therapy Field for Malignant Astrocytoma and Glioblastoma Multiforme

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2002³â 20±Ç 3È£ p.199 ~ 205
Á¶Èï·¡, ÃÖ¿µ¹Î,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶Èï·¡ (  ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

ÃÖ¿µ¹Î (  ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

Abstract

¸ñÀû: º» ¿¬±¸ÀÇ ¸ñÀûÀº ¾Ç¼º ¼º»ó¼¼Æ÷Á¾ ¹× ±³¸ð¼¼Æ÷Á¾ ȯÀÚµéÀÇ ¹æ»ç¼± Ä¡·á ½Ã °¡Àå ÀûÀýÇÑ Á¶»ç ¿µ¿ªÀ» ¾Ë¾Æº¸°íÀÚ ½ÃÇàÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1994³â 1¿ùºÎÅÍ 2000³â 3¿ù±îÁö ¾Ç¼º ¼º»ó¼¼Æ÷Á¾ ¹× ±³¸ð¼¼Æ÷Á¾À¸·Î Áø´ÜµÇ¾î ¼ö¼ú ¹× ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ÈÄ MRI·Î ÃßÀû°üÂûÀÌ ½ÃÇàµÈ ȯÀÚ Áß Àç¹ßÀÌ È®ÀÎµÈ 21 ¸íÀ» ´ë»óÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ¿ø¹ß º´¼Ò ¹Ù±ù °æ°è¿¡¼­ºÎÅÍ Ã³À½ Àç¹ßÀÌ È®ÀεÈ
º´¼Ò±îÁöÀÇ °Å¸®¸¦ ÃøÁ¤ÇÏ¿´´Ù. ±× ¿Ü¿¡ Á¾¾çÀÇ Å©±â, ºÎÁ¾ÀÇ Á¤µµ, ¼ö¼ú ÀýÁ¦ÀÇ ¹üÀ§, °¨¸¶³ªÀÌÇÁ¸¦ ÀÌ¿ëÇÑ Á¤À§¹æ»ç¼±¼ö¼ú, ´Ù¹ß¼º º´º¯ µîÀÌ Àç¹ß ¾ç»ó¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÏ¿© ºÐ¼®À» ÇÏ¿´´Ù.

°á°ú: ÃÑ 21¸í Áß 18¸í(86%)ÀÌ 2 §¯ À̳»¿¡¼­ Àç¹ßÀ» ÇÏ¿´´Ù. À̵é Áß 1 §¯ À̳»°¡ 12¸í, 1¡­2 §¯ »çÀÌÀÇ Àç¹ßÀÌ 6¸íÀ̾ú´Ù. ³ª¸ÓÁö 3¸íÀÇ Àç¹ßÀº 3 §¯, 4 §¯, 5 §¯, ¶³¾îÁ®¼­ °¢°¢ Àç¹ßÀ» ÇÏ¿´´Ù. 2 §¯ ÀÌ»ó ¶³¾îÁ® Àç¹ßÇÑ 3¸íÀº ¸ðµÎ ´Ù¹ß¼º º´º¯ÀÌ ÀÖ´Â
ȯÀÚ¿´´Ù. Á¾¾çÀÇ Å©±â, ºÎÁ¾ÀÇ ¹üÀ§, ¼ö¼ú ÀýÁ¦ÀÇ ¹üÀ§, °¨¸¶³ªÀÌÇÁ ½ÃÇà À¯¹«¿¡ µû¸¥ Àç¹ßÀÇ ¾ç»ó¿¡ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ´Ù¸¸ ´Ù¹ß¼º º´º¯ÀÏ °æ¿ì ´õ ¸Ö¸®¼­ Àç¹ßÇÏ´Â °æÇâÀ» º¸¿´´Ù.

°á·Ð: ¾Ç¼º ¼º»ó¼¼Æ÷Á¾ ¹× ±³¸ð¼¼Æ÷Á¾¿¡¼­ Àç¹ß ¾ç»óÀº ¿ø¹ß º´¼Ò ÁÖÀ§ÀÇ 2 §¯ À̳» Àç¹ßÀÌ ÁÖ Àç¹ß ¾ç»óÀ̾ú´Ù. ¹æ»ç¼± Á¶»ç¿µ¿ªÀÇ ³ÐÀÌ´Â ºÎÁ¾ÀÇ ¹üÀ§³ª, º´¼ÒÀÇ Å©±â, °¨¸¶ ³ªÀÌÇÁ ¼ö¼ú µî¿¡ µû¶ó ´õ ³ÐÈú ÇÊ¿ä´Â ¾ø´Â °ÍÀ¸·Î ÆǴܵȴÙ. ±×·¯³ª ´Ù¹ß¼º
º´º¯ÀÇ
°æ¿ì¿¡´Â ´ÜÀÏ º´¼Òº¸´Ù ´õ ³ÐÀº Á¶»ç ¹üÀ§°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose: This study was performed to determine the optimal radiation therapy field for the treatment of malignant astrocytoma and glioblastoma multiforme.

Materials and Methods: From Jan. 1994 to Mar. 2000, 21 patients with malignant astrocytoma and glioblastoma multiforme, confirmed as recurrent by follow up MRI after surgery and radiation therapy, were analyzed. The distance from the
margin
of
the primary lesion to the recurrent lesion was measured. The following factors were analyzed to investigate the influence of these factors to recurrence pattern; tumor size, degree of edema, surgical extent, gamma knife radiosurgery and multiple
lesions.

Results: Among the 21 patients, 18 (86%) were recurred within 2 §¯ from the primary lesion site. 12 within 1 §¯, 6 between 1 and 2 §¯. The other 3 patients all with multiple lesions, were recurred at 3, 4, 5 §¯, from the primary lesion
site.
The
recurrence pattern was not influenced by the factors of tumor size, extent of edema, surgical extent, or gamma knife radiosurgery. However, patients with multiple lesions showed a tendency of recurrence at sites further from the primary
lesion.

Conclusions: Most (86%) of the recurrences of malignant astrocytoma and glioblastoma multiforme occurred within 2 §¯ from the primary lesion site. The width of treatment field does not need to be changed according to tumor size, degree of
edema,
surgical extent, or gamma knife radiosurgery. However, the treatment field for multiple lesions appears to be wider than that for a single lesion.

Å°¿öµå

¾Ç¼º ¼º»ó¼¼Æ÷Á¾; ±³¸ð¼¼Æ÷Á¾; MRI; Àç¹ß¾ç»ó; ¹æ»ç¼± Á¶»ç¿µ¿ª; Malignant astrocytoma; Glioblastoma multiforme; MRI; Recurrence pattern; Radiation treatment field;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS